BVAXF Biovaxys Technology Corporation (QB)

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

 

For the Month of June 2022

 

Commission File Number: 001-37353

 

BIONDVAX PHARMACEUTICALS LTD.

(Translation of registrant’s name into English)

 

Jerusalem BioPark, 2nd Floor

Hadassah Ein Kerem Campus

Jerusalem, Israel

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒     Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

 

 

 

On June 7, 2022, BiondVax Pharmaceuticals Ltd. (the “Company”) issued a press release announcing the receipt of supportive Scientific Advice from the Paul Ehrlich Institute for the Company’s COVID-19 NanoAb development plans. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 6-K.

 

Exhibit Index

 

Exhibit No.		Description
99.1		Press Release dated June 7, 2022

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	BiondVax Pharmaceuticals Ltd.
Date: June 8, 2022	By:	/s/ Amir Reichman
		Amir Reichman
		Chief Executive Officer

 

 

2